9 April 2021 in Nature Communications
Lack of detailed knowledge of SARS-CoV-2 infection has been hampering the development of treatments for coronavirus disease 2019 (COVID-19). Here, we report that RNA triggers the liquid–liquid phase separation (LLPS) of the SARS-CoV-2 nucleocapsid protein, N. By analyzing all 29 proteins of SARS-CoV-2, we find that only N is predicted as an LLPS protein. We further confirm the LLPS of N during SARS-CoV-2 infection. Among the 100,849 genome variants of SARS-CoV-2 in the GISAIDdatabase, we identify that ~37% (36,941) of the genomes contain a specific trio-nucleotide polymorphism (GGG-to-AAC) in the coding sequence of N, which leads to the amino acid substitutions, R203K/G204R. Interestingly, NR203K/G204Rexhibits a higher propensity to undergo LLPS and a greater effect onIFNinhibition. By screening the chemicals known to interfere with N-RNA binding in other viruses, we find that (-)-gallocatechin gallate (GCG), a polyphenol from green tea, disrupts the LLPS of N and inhibits SARS-CoV-2 replication. Thus, our study reveals that targeting N-RNA condensation with GCG could be a potential treatment for COVID-19.
18 March 2026 in Nature Communications
Systemic lupus erythematosus (SLE) has a complex, multifactorial etiology, which contributes to a lack of definitive cure and limited treatment efficacy. Here, we report that cyclic GMP-AMP synthase (cGAS) is significantly activated in SLE patients. We further demonstrate that cGAS deletion protects mice from lupus-like symptoms induced by the TLR7 agonist imiquimod (IMQ). In a screen of 3,159 FDA-approved drugs, we identify the antiplatelet agent prasugrel as a potent cGAS inhibitor. Mechanistically, prasugrel disrupts the DNA-triggered liquid phase condensation and activation of cGAS via direct acetylation. Strikingly, we find that prasugrel exhibits remarkable efficacy in treating SLE in both mouse models and patient cells. Importantly, we report elevated plasma cyclic GMP-AMP (cGAMP) in SLE patients and identify it as a potential biomarker for predicting prasugrel response. Thus, our work elucidates the essential role of cGAS in SLE pathogenesis and presents prasugrel as a promising therapeutic option with immediate translational potential.
20 October 2026 in Biochemical and Biophysical Research Communications
2 June 2026 in Research Square
The integrated stress response (ISR) is a conserved signaling network that enables cells to adapt to environmental stresses, and its dysregulation is implicated in numerous human diseases1. Although ISR activation is a cell-autonomous event, pathological tissues frequently display coordinated ISR activation across many cells. Whether local ISR activation spreads beyond the initially affected cells, and whether such spread contributes to pathology, remain poorly understood. Here, we identify the intercellular transmission of stress granules (SGs), a process we term Cell-to-cell Transmission of SGs (CTS), as the pivotal mechanism for ISR propagation. We show that, once formed, the SGs are released via TMED10-dependent unconventional secretion pathway and internalized by neighboring cells through macropinocytosis. This CTS event is sufficient to instigate ISR in recipient cells in a PERK- and GCN2-dependent manner, thereby broadcasting the stress state across cell populations. Ablation of G3BP1 in donor cells to prevent SGs formation, or inhibition of their secretion with 3-Methyladenine, potently suppressed ISR propagation. Consistently, disruption of macropinocytosis blocked SG uptake in recipient cells and consequently inhibited ISR. Crucially, in a murine model of renal ischemia-reperfusion injury, targeting either SGs formation, secretion, or uptake significantly mitigated tissue damage. These findings provide a mechanistic explanation for how the ISR expands from a cellular to a tissue scale and establish CTS as a therapeutically tangible target for mitigating ISR-associated pathologies.
17 November 2026 in Nature Immunology